- Home
- NAMS vs ZLAB Comparison
NAMS vs ZLAB Comparison
Compare NAMS & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAMS
- ZLAB
- Stock Information
- Founded
- NAMS 2019
- ZLAB 2013
- Country
- NAMS Netherlands
- ZLAB China
- Employees
- NAMS N/A
- ZLAB N/A
- Industry
- NAMS Biotechnology: Pharmaceutical Preparations
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- NAMS Health Care
- ZLAB Health Care
- Exchange
- NAMS Nasdaq
- ZLAB Nasdaq
- Market Cap
- NAMS 2.7B
- ZLAB 3.0B
- IPO Year
- NAMS N/A
- ZLAB 2017
- Fundamental
- Price
- NAMS $23.33
- ZLAB $26.06
- Analyst Decision
- NAMS Strong Buy
- ZLAB Strong Buy
- Analyst Count
- NAMS 7
- ZLAB 3
- Target Price
- NAMS $38.17
- ZLAB $55.00
- AVG Volume (30 Days)
- NAMS 538.3K
- ZLAB 477.2K
- Earning Date
- NAMS 02-06-2025
- ZLAB 02-25-2025
- Dividend Yield
- NAMS N/A
- ZLAB N/A
- EPS Growth
- NAMS N/A
- ZLAB N/A
- EPS
- NAMS N/A
- ZLAB N/A
- Revenue
- NAMS $33,594,000.00
- ZLAB $355,748,000.00
- Revenue This Year
- NAMS $131.53
- ZLAB $49.04
- Revenue Next Year
- NAMS N/A
- ZLAB $46.70
- P/E Ratio
- NAMS N/A
- ZLAB N/A
- Revenue Growth
- NAMS 78.77
- ZLAB 35.01
- 52 Week Low
- NAMS $15.19
- ZLAB $13.48
- 52 Week High
- NAMS $27.29
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- NAMS 44.28
- ZLAB 49.34
- Support Level
- NAMS $23.17
- ZLAB $23.82
- Resistance Level
- NAMS $26.71
- ZLAB $27.24
- Average True Range (ATR)
- NAMS 0.94
- ZLAB 1.29
- MACD
- NAMS -0.40
- ZLAB 0.15
- Stochastic Oscillator
- NAMS 23.65
- ZLAB 60.84
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.